Acasti Pharma Shares to Trade on NASDAQ

Acasti Pharma Shares to Trade on NASDAQ

LAVAL, Quebec, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti")
(Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc.
("Neptune") subsidiary, is pleased to announce that it has been approved to
list its common shares on the NASDAQ Capital Market beginning on January 7,
2013 under the ticker symbol "ACST."

"The listing of our common shares on the NASDAQ is an important milestone for
Acasti," stated Xavier Harland, Chief Financial Officer. "We believe our new
listing will provide Acasti greater exposure to investors in the U.S. and
around the world and reflects our effort to increase liquidity for our
shareholders," he added.

"We're completing an important part of Acasti's development plan with this
listing. As set forth in Acasti's business plan, the NASDAQ listing should be
followed by the expected completion of the open label clinical trial," said
Harlan Waksal, Executive Vice-President. "There are multiple US institutional
funds that are restricted from investing in shares that trade on foreign
exchanges. We therefore believe that Acasti's NASDAQ listing will broaden its
base of potential shareholders," he added.

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel
long-chain omega-3 phospholipids. Phospholipids are the major component of
cell membranes and are essential for all vital cell processes. They are one of
the principal constituents of High Density Lipoprotein (good cholesterol) and,
as such, play an important role in modulating cholesterol efflux. Acasti
Pharma's proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have
substantial health benefits and which are stabilized by potent antioxidants.
Acasti Pharma is focusing initially on treatments for chronic cardiovascular
and cardiometabolic conditions within the over-the-counter, medical food and
prescription drug markets.

"Neither NASDAQ nor the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or
current fact constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities
laws. Such forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the actual results
of the Company to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. In
addition to statements which explicitly describe such risks and uncertainties,
readers are urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or "plans" to be
uncertain and forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that are described
from time to time in the Company's reports filed with the Securities and
Exchange Commission and the Canadian securities commissions.

CONTACT: Acasti Contact:
         Xavier Harland
         Chief Financial Officer
         +1.450.687.2262
         x.harland@acastipharma.com
         www.acastipharma.com
        
         Howard Group Contact:
         Dave Burwell
         (888) 221-0915
         dave@howardgroupinc.com
         www.howardgroupinc.com
 
Press spacebar to pause and continue. Press esc to stop.